ClinicalTrials.gg
RecruitingNCT07944547AEGISUpdated Nov 18, 2026

APL-1702 Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade II/III (CIN2/3)

An interventional study of APL-1702 and APL-1702 in Cervical Intraepithelial Neoplasia Grade 2/3 and Human Papillomavirus Infection, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Xiangya Hospital of Central South University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2025, registered Nov 2026).
  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 68 studies in Papillomavirus Infections with a site in China — 26 open to participants now, 39 under way, 10 of them phase 3. Papillomavirus Infections · China.

Planned enrollment
31st of 44
159 · median 510
Started
2025
with 4 others
No phase
6 of 68
5 open now
Primary completion
2028-01
later than 26 of 38 live
Registered
68th of 68
by date

Among the 68 studies in Papillomavirus Infections with a site in China, this one is the 31st largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2025, is one of 6 with no phase, reaches primary completion later than 26 of the 38 other live ones, and was the 68th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 134 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

26 of the 68 studies in Papillomavirus Infections with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Papillomavirus Infections studies recruiting now, 39 (44%) set no upper age limit and 44 (50%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Papillomavirus Infections with a site in China, or all of them as a file.
02

Study summary

This investigator-initiated, open-label, exploratory study evaluates the safety and preliminary efficacy of APL-1702 photodynamic therapy in participants with high-risk human papillomavirus (hrHPV)-positive cervical intraepithelial neoplasia grade 2 (CIN2) or grade 3 (CIN3). Part 1 enrolls adults with CIN2 into six treatment-regimen groups to identify a preferred regimen, primarily on the basis of histological regression at Week 24 after the first treatment. Part 2 enrolls adults aged 18 to 45 years with hrHPV-positive CIN3 and evaluates three treatments administered at Day 0, Month 1, and Month 3. Participants are assessed for histological regression, hrHPV clearance, and safety.

03

Conditions studied

  • Cervical Intraepithelial Neoplasia Grade 2/3
  • Human Papillomavirus Infection

Keywords

  • CIN2
  • CIN3
  • high-risk HPV
  • APL-1702
  • HAL-PDT
  • photodynamic therapy
  • drug-device combination
  • histopathological regression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in this study, understanding of the study procedures, and ability to provide written ;
  2. Part 1 Age ≥18 years; Part 2 Age≥18 years and≤45 years
  3. CIN histology: Part 1, hrHPV-positive and confirmed CIN2 within 3 months before the first treatment; Part 2, hrHPV-positive and histologically confirmed CIN3 within 3 months before the first treatment, with the lesion involving 50% or less of the cervical area. Histological eligibility is confirmed by the central laboratory.
  4. Adequate colposcopic examination, with the entire cervical transformation zone and squamocolumnar junction visible and the entire lesion margin visible.
  5. A strong desire to preserve cervical structure and/or function, and the investigator considers non-surgical treatment acceptable.
  6. The investigator considers the cervical size suitable for placement of the APL-1702 device
  7. Negative pregnancy test; no pregnancy planned from study initiation until 3 months after the last treatment or 24 weeks after the first treatment, whichever is later. Participants must have abstained from sexual activity or used effective from the end of the last menstrual period to study entry and must agree to use condoms during the protocol-defined contraceptive period.

Exclusion criteria

Exclusion Criteria:

  1. Cervical adenocarcinoma in situ (AIS), other glandular epithelial lesions, invasive cervical cancer, or suspected malignant lesions.
  2. Lesions extending to the vaginal wall, endocervical canal, vaginal fornix, or vulvar region.
  3. Previous physical or surgical treatment of the cervix resulting in incomplete cervical structure (for example, cold knife conization), or physical or surgical treatment for CIN2 or CIN3 after the current histopathological diagnosis.
  4. The first study treatment occurs within 7 half-lives after the last dose of an antiviral medication.
  5. History of toxic shock syndrome.
  6. Severe pelvic inflammatory disease, severe cervicitis, or other serious gynecological infections identified by colposcopy or clinical examination.
  7. The investigator considers that vaginal bleeding during treatment may affect treatment efficacy.
  8. Administration of any inactivated vaccine within 2 weeks before study treatment or any within 4 weeks before study treatment.
  9. Unresolved severe cardiovascular, neurological, psychiatric, endocrine, or hematologic diseases; known severe immunodeficiency; need for long-term or therapy; or a history of within 5 years.
  10. immunosuppression, confirmed disease, or primary immunodeficiency.
  11. Known or screening-detected active sexually transmitted diseases (STDs), including but not limited to infection, syphilis, or genital herpes, unless adequately treated with negative results before study treatment.
  12. Presence of a cardiac pacemaker.
  13. Suspected or known porphyria, or known allergy to the study drug or chemically related compounds.
  14. Allergy to silicone.
  15. Pregnant or breastfeeding.
  16. Childbirth or miscarriage within 6 weeks before enrollment.
  17. Participation in another clinical trial within 30 days before study treatment.
  18. Poor compliance or investigator's judgment that the subject is unsuitable for participation.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    Part 1 - Q3W x 3

    Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 3 treatments.

    Drug: APL-1702

  • Experimental
    Part 1 - Q3W x 6

    Adults with hrHPV-positive CIN2 receive APL-1702 once every 3 weeks for a total of 6 treatments.

    Drug: APL-1702

  • Experimental
    Part 1 - Q2W x 3

    Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 3 treatments.

    Drug: APL-1702

  • Experimental
    Part 1 - Q2W x 6

    Adults with hrHPV-positive CIN2 receive APL-1702 once every 2 weeks for a total of 6 treatments.

    Drug: APL-1702

  • Experimental
    Part 1 - Q1W x 3

    Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 3 treatments.

    Drug: APL-1702

  • Experimental
    Part 1 - Q1W x 6

    Adults with hrHPV-positive CIN2 receive APL-1702 once weekly for a total of 6 treatments.

    Drug: APL-1702

  • Experimental
    Part 2 - Month 0/1/3

    Adults aged 18 to 45 years with hrHPV-positive CIN3 receive a total of three APL-1702 treatments.

    Drug: APL-1702

Interventions

  • DrugAPL-1702

    APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 3.

  • DrugAPL-1702

    APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q3W x 6.

  • DrugAPL-1702

    APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 3.

  • DrugAPL-1702

    APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q2W x 6.

  • DrugAPL-1702

    APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 3.

  • DrugAPL-1702

    APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Q1W x 6.

  • DrugAPL-1702

    APL-1702 consists of 5% hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic light delivery device (CL7). It is placed by a gynecologist in an outpatient setting; the participant leaves after placement and removes the device after treatment as instructed. Regimen: Day 0, Month 1, and Month 3 (3 treatments total).

06

What researchers measure

Primary outcomes

  1. Part 1: Histological regression rate at Week 24 after the first treatment

    Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens.

    Time frame: Week 24 after the first treatment

  2. Part 2: Histological regression rate at Week 24 after the first treatment

    Proportion of Part 2 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only, based on central laboratory evaluation of colposcopy-directed cervical biopsy specimens.

    Time frame: Week 24 after the first treatment

Secondary outcomes

  1. Part 1 hrHPV clearance rate

    Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

    Time frame: 28 days after the final treatment course and Week 24 after the first treatment

  2. Part 1 incidence and characteristics of adverse events and serious adverse events

    Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events.

    Time frame: From informed consent through Week 96 after the first treatment

  3. Part 1 long-term hrHPV clearance rate

    Proportion of Part 1 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

    Time frame: Weeks 36, 60, and 96 after the first treatment

  4. Part 1 long-term histological regression rate

    Proportion of Part 1 participants whose post-treatment cervical histopathology is normal, CIN1, or inflammatory changes only.

    Time frame: Weeks 36, 60, and 96 after the first treatment

  5. Part 2 hrHPV clearance rate

    Proportion of Part 2 participants in whom all hrHPV genotype(s) detected at baseline are undetectable after treatment.

    Time frame: Week 24 after the first treatment

  6. Part 2 incidence and characteristics of adverse events and serious adverse events

    Type, incidence, severity, duration, outcome, and relationship to the study product of adverse events and serious adverse events.

    Time frame: From informed consent through Week 48 after the first treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2028, 32 months after the start.

Of 109 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 32 months is above that.

Counting every sponsor, half of 118 studies reached it within 26 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartActual
May 26, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944547
Responsible party
Yu Zhang (Chief Physician, Xiangya Hospital of Central South University) — Principal investigator
First posted
Nov 18, 2026
Start date
May 26, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Yu Zhang, MD
Contact
cszhangyu@126.com
0731-89753999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion